Amneal Pharmaceuticals (AMRX) Other Non Operating Income (2017 - 2026)

Amneal Pharmaceuticals has reported Other Non Operating Income for 10 years, with the latest figure at -$2.0 million in Q2 2026.

• On a quarterly basis, Other Non Operating Income fell 123.62% year-over-year to -$2.0 million in Q2 2026; TTM through Jun 2026 was -$41.2 million, a 342.99% decrease from a year earlier, with the FY2025 full-year figure at -$31.4 million, down 366.51% from the prior year.
• Other Non Operating Income was -$2.0 million for Q2 2026 at Amneal Pharmaceuticals, up from -$7.8 million in the prior quarter.
• The five-year high for Other Non Operating Income was $8.3 million in Q2 2025, with the low at -$47.4 million in Q4 2023.
• Average Other Non Operating Income over 5 years is -$2.4 million, with a median of $2.2 million recorded in 2024.
• The sharpest annual moves came in 2024 and 2025: Other Non Operating Income soared 935.63% in 2024, then tumbled 1480.83% in 2025.
• Over 5 years, Other Non Operating Income stood at $3.7 million in 2022, then sank by 1383.73% to -$47.4 million in 2023, then surged by 104.58% to $2.2 million in 2024, then plunged by 101.61% to -$35000.0 in 2025, then plunged by 5471.43% to -$2.0 million in 2026.
• The last three Other Non Operating Income figures came in at -$2.0 million (Q2 2026), -$7.8 million (Q1 2026), and -$35000.0 (Q4 2025), per Business Quant data.